Lantheus Holdings (FRA:0L8) Total Liabilities : €815 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Lantheus Holdings Total Liabilities?

Lantheus Holdings's Total Liabilities for the quarter that ended in Mar. 2024 was €815 Mil.

Lantheus Holdings's quarterly Total Liabilities declined from Sep. 2023 (€771.01 Mil) to Dec. 2023 (€765.93 Mil) but then increased from Dec. 2023 (€765.93 Mil) to Mar. 2024 (€814.93 Mil).

Lantheus Holdings's annual Total Liabilities increased from Dec. 2021 (€353.42 Mil) to Dec. 2022 (€825.16 Mil) but then declined from Dec. 2022 (€825.16 Mil) to Dec. 2023 (€765.93 Mil).

Lantheus Holdings Total Liabilities Historical Data

The historical data trend for Lantheus Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantheus Holdings Total Liabilities Chart

Lantheus Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

262.19

292.32

353.42

825.16

765.93

Lantheus Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															844.12	724.62	771.01	765.93	814.93

Lantheus Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Lantheus Holdings's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	171.8	+	(564.985	+	29.146
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	766

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1514.104	-	748.173
	=	766

Lantheus Holdings's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	218.222	+	(567.263	+	29.445
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	815

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	1684.827	-	869.897
	=	815

Lantheus Holdings Total Liabilities Related Terms

Thank you for viewing the detailed overview of Lantheus Holdings's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Lantheus Holdings (FRA:0L8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (FRA:0L8) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

LNTH:USA 0L8:Germany

Address

201 Burlington Road, South Building, Bedford, MA, USA, 01730

Website

https://www.lantheus.com

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Lantheus Holdings (FRA:0L8) Headlines

No Headlines